Neuren Pharmaceuticals (NEU) H1 2026 earnings summary

Executive summary

• Announced first-ever dividend program, with a fully franked interim dividend of 15 cents per share for H1 2026, reflecting a 90% payout of available royalty income.

• Maintained a robust cash position of A$287 million as of June 30, 2026, fully funding all NNZ-2591 programs and ongoing development.

• DAYBUE achieved significant milestones: European approval, strong U.S. sales, launch of new STIX formulation, and inclusion as standard of care in multiple regions.

• NNZ-2591 phase III KOALA trial for Phelan-McDermid syndrome progressing, with 15 sites enrolling and strong patient interest; open-label extension underway.

• Net profit after tax for H1 2026 was A$4.9 million, reflecting higher R&D costs and lower milestone receipts.

Financial highlights

• H1 2026 royalty income rose 29% year-over-year to US$23.3 million (A$33.2 million), with full-year guidance of US$52.6–56.2 million based on DAYBUE net sales guidance of US$480–510 million.

• Corporate and admin costs for H1 2026 were A$3.0 million, fully offset by A$5.6 million in interest income.

• R&D investment increased to A$27.4 million in H1 2026, mainly due to NNZ-2591 Phase 3 trial progression.

• Interim dividend of A$0.15 per share, fully franked, to be paid October 7, with H1 2026 payout amounting to A$19.0 million.

• Net cash from operating activities was A$8.0 million, down from A$128.3 million in H1 2025 due to lower milestone receipts.

Outlook and guidance

• Full-year 2026 royalty income expected at US$52.6–56.2 million, with anticipated global DAYBUE net sales of US$480–510 million.

• Next U.S. milestone payment ($50 million) triggered when North American sales exceed $500 million; European launch to trigger $35 million milestone.

• Japan topline trial results expected September–November 2026, with regulatory submission planned for 2027.

• Acadia forecasts $700 million global DAYBUE sales by 2028.

• NNZ-2591 KOALA trial enrollment progressing well; formal guidance on top-line results to be provided after further enrollment milestones.